Venous thromboembolism (VTE) and cancer are two major public health issues that are
closely linked. Cancer is part of the major risk factors for VTE and it is estimated
that up to 20% of cancer patients will face a VTE issue during the course of their
malignancy [
1
,
2
]. Patients who develop VTE during the course of their malignancy are at high risk
for VTE recurrence: 10 to 17% of them will experience a new VTE event within the first
six months of anticoagulation [
[3]
]. However, this risk varies depending on several parameters such as cancer site, cancer
histology, or cancer stage [
[4]
].Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Incidence of venous thromboembolism and its effect on survival among patients with common cancers.Arch Intern Med. 2006; 166: 458-464
- Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study.Arch Intern Med. 2000; 160: 809-815
- Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis.Thromb Res. 2014; 134: 1214-1219
- Risk of recurrent venous thromboembolism according to malignancy characteristics in patients with cancer-associated thrombosis: a systematic review of observational and intervention studies.Blood Coagul Fibrinolysis. 2011; 22: 86-91
- Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism.Circulation. 2012; 126: 448-454
- Validation of the clinical prediction rule for recurrent venous thromboembolism in cancer patients: the Ottawa score.Support Care Cancer. 2013; 21: 2309-2313
- Validation of the Ottawa prognostic score for the prediction of recurrent venous thromboembolism in patients with cancer-associated thrombosis.J Thromb Haemost. 2013; 11: 998-1000
Article info
Publication history
Published online: August 31, 2016
Accepted:
August 2,
2016
Received:
July 29,
2016
Identification
Copyright
© 2016 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
